Leukemia

Florida Homeowner Reaches Settlement in Phosphate Mining Radiation Case

Retrieved on: 
Wednesday, March 27, 2024
Chemicals, Plastics, Health, Legal, Manufacturing, Environmental Issues, Environmental Health, Residential Building & Real Estate, Commercial Building & Real Estate, Professional Services, Construction & Property, Oncology, Environment, Mining, Minerals, Natural Resources, Lymphoma, Risk, Radiation, Uranium, EPA, Cancer, Leukemia, Uranium mining

Drummond conducted phosphate mining for several years in the Central Florida region before developing the Oakbridge and Grasslands neighborhoods for commercial and residential use in the 1980s.

Key Points: 
  • Drummond conducted phosphate mining for several years in the Central Florida region before developing the Oakbridge and Grasslands neighborhoods for commercial and residential use in the 1980s.
  • Radiation from decaying uranium is a known byproduct of phosphate mining.
  • EPA testing before development of the subdivisions showed radiation levels 11 to 21 times higher than the acceptable risk limit.
  • In 2003, the EPA’s Florida Phosphate Initiative noted that some homes had median radiation concentrations four to 22 times higher than pre-mined land and gamma exposure two to three times higher than normal.

Egle Therapeutics Strengthens its Leadership Team with the Appointment of Monica Gostissa, PhD, as Chief Scientific Officer and Reno Winter, PhD, as Chief Technical Officer

Retrieved on: 
Wednesday, March 27, 2024
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Egle, Natural science, Leukemia, Patient, Cell biology, CMC, Head, Doctor of Philosophy, MD, IND, Clinical trial, Investigational New Drug, Therapy, International school, CSO, Pharmaceutical industry

Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appointment of Monica Gostissa, PhD, as Chief Scientific Officer and Reno Winter, PhD, as Chief Technical Officer.

Key Points: 
  • Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appointment of Monica Gostissa, PhD, as Chief Scientific Officer and Reno Winter, PhD, as Chief Technical Officer.
  • “I'm excited to join Egle Therapeutics to help develop novel immunotherapies targeting T regulatory cells for oncology and autoimmune diseases.
  • “I am happy to be part of Egle Therapeutics’ leadership team to contribute my expertise in CMC and beyond to the company’s mission.
  • Dr. Winter is a trained biochemist and received his PhD in Natural Sciences from the Martin Luther University Halle-Wittenberg, Germany.

United States In-Vitro Diagnostics Market Analysis 2023-2030: Technological Advancements Drive IVD Adoption, Enhancing Patient Outcomes Fueling Demand - ResearchAndMarkets.com

Retrieved on: 
Friday, March 22, 2024
Biotechnology, Baby, Maternity, Health, General Health, Health Technology, Medical Devices, Research, Hospitals, Genetics, Consumer, Science, Automation, PCR, Cardiovascular disease, Hematology, Haemophilia, Diabetes, Ageing, American Cancer Society, Tissue, Cancer, IVD, Leukemia, Workflow, Anemia, Blood, Medical device

The market is poised for growth with the development of automatic IVD structures that provide improved efficiency, accuracy, and throughput.

Key Points: 
  • The market is poised for growth with the development of automatic IVD structures that provide improved efficiency, accuracy, and throughput.
  • This reflects a commitment to enhancing patient care through innovative technology and positioning the United States at the forefront of the in-vitro diagnostics market.
  • Technological advancements are set to propel the United States in the in vitro diagnostics (IVD) market.
  • Instruments are predicted to be among the leading products in the United States in vitro diagnostics (IVD) market.

Cotchett, Pitre & McCarthy Files Lawsuit on Behalf of Residents of Maywood, CA, for Exposure to Cancer Causing Ethylene Oxide

Retrieved on: 
Monday, March 18, 2024
Professional Services, Legal, Environment, Bone marrow, Public health, Inhalation, National Cancer Institute, Breast, Ethylene oxide, Cancer, Leukemia, Ethylene, Aplastic anemia, Complaint, Atmosphere, Breast cancer, Partner, Superior court, Family, Stomach, Spice, Los Angeles Times, Lymphoma, Stomach cancer, Oil

Cotchett, Pitre & McCarthy LLP filed a lawsuit on behalf of many longtime residents of Maywood, CA, next to Vernon, an industrial area, for their decades long exposure to cancer caused by carcinogenic Ethylene Oxide being released into the air.

Key Points: 
  • Cotchett, Pitre & McCarthy LLP filed a lawsuit on behalf of many longtime residents of Maywood, CA, next to Vernon, an industrial area, for their decades long exposure to cancer caused by carcinogenic Ethylene Oxide being released into the air.
  • Ethylene Oxide is used to sterilize medical equipment and spices but, during the process, some of the Ethylene Oxide escapes the facility into the surrounding air.
  • Ethylene Oxide is odorless and colorless, so nearby Maywood residents never knew it was in the air surrounding their homes.
  • According to the National Cancer Institute, and other protective health agencies around the world, Ethylene Oxide is associated with breast cancer, stomach cancer, lymphoma, and leukemia.

Global Cord Blood & Tissue Banking Industry Market Size, Segmentation & Forecast Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 15, 2024
Health, Biotechnology, Catalent, Transplant, Cell, Patient, UCB, LifeCell International, Microsoft Exchange Server, Organization, Regenerative medicine, Cryo-Cell International, Spectrum, Disorder, Umbilical cord, Population growth, Stemcell Technologies, Certification, HSCT, NIH, GMP, Cord blood, The Cooper Companies, Safety, Hematopoietic stem cell transplantation, Artivion, DSM-IV codes, Tissue, Research, Acquisition, Cancer, Leukemia, CBR, Cryopreservation, Cerebral palsy, FDA, CBUS, Sickle cell disease, ClinicalTrials.gov, Registry, Amniotic fluid, Hearing loss, GCBC, MNC, Geography

The "Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2024" report has been added to ResearchAndMarkets.com's offering.
  • There are now over 800,000 cord blood units stored in public cord blood banks and more than 6.75 million cord blood and tissue units stored within private banks worldwide.
  • Today, nearly all U.S. cord blood banks and approximately one-third of global cord blood banks offer cord tissue storage.
  • The report presents findings on the following topics:
    Rate per cord blood unit in the U.S. and Europe
    Number of clinical trials, number of published scientific papers, and amount of NIH funding for cord blood research
    Number and types of patents for cord blood, cord tissue, and placental products
    The report presents a comprehensive analysis of the global cord blood and tissue banking market.

Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029: Pioneering New Drug Class with Versatile Therapeutic Potential - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 14, 2024
Other Health, Health, Science, Pharmaceutical, Research, Multiple myeloma, Toxicity, Antigen, Haemophilia A, Cell, Autoimmunity, Patent, Carcinoma, Risk, Inflammation, Haemophilia, Malignancy, Monoclonal antibody, Neoplasm, Tissue, Patient, Tumor microenvironment, Antibody, Cancer, Bladder cancer, Leukemia, Diabetic retinopathy, Indication, Cytokine, Immune system, Therapy, Infection, Priority, Physician, Engineering, Escape Room, Acute lymphoblastic leukemia, Vaccine

The "Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering.
  • Bispecific antibodies are engineered proteins intended to simultaneously bind two different antigens, typically found on distinct cell types.
  • Therefore, bispecific antibodies have demonstrated enough clinical success to validate their potential as a major new drug class.
  • Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029 Report Highlights:
    Bispecific Antibodies Development Proprietary Platforms Insight: > 30 Platforms
    Global Bispecific Antibodies Market Size 2023: > USD 8 Billion
    Clinical & Commercial Insight on Approved Bispecific Antibodies: 12 Antibodies
    Global Bispecific Antibodies Clinical Trials by Company, Indication & Phase: > 800 Antibodies
    FDA & EMA Fast Track Approval, Orphan Designation, Priority Status Insights

First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation

Retrieved on: 
Wednesday, March 13, 2024
Oncology, Philanthropy, Health, Foundation, Pharmaceutical, Cardiology, Biotechnology, Diagnosis, Bone marrow, Chronic lymphocytic leukemia, Entrepreneurship, CLL, Health equity, Patient, Humanitarianism, Cancer, Leukemia, BeiGene, Access, Multimedia, Physician, Developing country, Medicine, Pharmaceutical industry

As a member of the Humanitarian PACT, BeiGene provided a monetary grant through the BeiGene Foundation and is providing BRUKINSA free of charge for eligible patients in a number of low- and middle-income countries.

Key Points: 
  • As a member of the Humanitarian PACT, BeiGene provided a monetary grant through the BeiGene Foundation and is providing BRUKINSA free of charge for eligible patients in a number of low- and middle-income countries.
  • “BeiGene and Max share a commitment to advance global health equity and ensure that patients in underserved regions have access to the best possible cancer care.
  • BeiGene and Max aim to provide access to CLL treatment to patients in need in 29 low- and middle-income countries.
  • Upon patient identity verification and CLL diagnosis confirmation, Max will deliver the treatment directly to the health institution providing care to the patient through well-established supply chains.

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China

Retrieved on: 
Wednesday, March 13, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, SLL, CLL, Hematology, E-3, Incidence, Patient, Malignancy, BCL2, Cancer, Leukemia, Death, IND, Clinical trial, Investigational New Drug, HKEX, BTK, Safety, Marketing, NRDL, Lymphoma, CD19, Pharmaceutical industry

This multicenter, randomized-controlled, open-label clinical study is designed to evaluate the efficacy and safety of ICP-248 combined with orelabrutinib versus immunochemotherapy in treatment-naive patients with CLL/SLL.

Key Points: 
  • This multicenter, randomized-controlled, open-label clinical study is designed to evaluate the efficacy and safety of ICP-248 combined with orelabrutinib versus immunochemotherapy in treatment-naive patients with CLL/SLL.
  • ICP-248 is a novel, orally bioavailable BCL2-selective inhibitor, which aims to treat hematologic malignancies as a monotherapy or in combination with other therapies.
  • BCL2 is an important regulatory protein of apoptosis pathway, and its abnormal expression is related to the development of various hematologic malignancies.
  • ICP-248 has an anti-tumor effect by selectively inhibiting BCL2 and restoring the mechanism of programmed cell death.

Cyclists Take On America's Most Beautiful Bike Ride In Support Of Blood Cancer Patients

Retrieved on: 
Wednesday, April 3, 2024
Diagnosis, Team In Training, Acute lymphoblastic leukemia, Bone marrow, University of Nevada, Reno, Leukemia & Lymphoma Society, Leukemia, Patient, SVP, Research, Perspiration, Cancer, University, RYE, Quality of life, LLS, Reader

RYE BROOK, N.Y., April 3, 2024 /PRNewswire/ -- Cyclists from across the country will help change the lives of blood cancer patients by gathering in Lake Tahoe on June 2, 2024 to participate in America's Most Beautiful Bike Ride. While working up a sweat and enjoying breathtaking views, riders' efforts will drive forward the work of The Leukemia & Lymphoma Society (LLS) to fund groundbreaking research, provide free patient support and assistance, and advocate on behalf of blood cancer patients and their families.

Key Points: 
  • In its efforts to reach and help all those impacted by a blood cancer diagnosis, LLS actively partners in communities across the country.
  • This year, LLS welcomes WVU Cancer Institute as America's Most Beautiful Bike's premier sponsor and new venue partner Tahoe Blue Event Center.
  • This year, America's Most Beautiful Bike Ride has chosen leukemia survivor Greg Carlson as the event's Honored Hero.
  • WHY: To support LLS and make an impact in the lives of all those affected by a blood cancer diagnosis.

BLACK HEALTH MATTERS TO HOST FREE SPRING HEALTH SUMMIT AND EXPO IN WASHINGTON, D.C.

Retrieved on: 
Wednesday, April 3, 2024
Kidney, Glucose, LDL, Exercise, Hepatitis C, Jabari, Black, BMS, National Pan-Hellenic Council, Patient, Vertex, Lunch, PSA, Legislation, Education, Gallaudet University, Omega Psi Phi, Incontinence, Johnson & Johnson, Cholesterol, WRC-TV, Triglyceride, Hypertension, Sanofi, Doctor of Pharmacy, Leukemia, Memory, Food, HDL, Phi Beta Sigma, Health, COVID-19 vaccine, Conference, BHM, COVID-19, All My Children, Howard University Hospital, Breakfast, Kidney disease, Diet, Guru, Sibley Memorial Hospital, Pharmaceutical industry

WASHINGTON, April 3, 2024 /PRNewswire/ -- Black Health Matters (BHM) – a leading nonprofit health advocacy organization that provides health and wellness information to the Black community – will host its annual Black Health Matters Spring Health Summit and Expo in Washington, D.C. on Saturday, April 13. As part of the award-winning health summit series, the free, one-day event will be held at the Kellogg Conference Hotel at Gallaudet University at 800 Florida Avenue, N.E., Washington, DC 20002 and includes celebrity hosts, medical professionals, health screenings, prizes, breakfast, and lunch. The event is open to the public and will begin at 8:30 a.m. with breakfast and conclude at 3:30 p.m.

Key Points: 
  • Popular health-focused event to feature free screenings, conversations with experts and celebrities
    WASHINGTON, April 3, 2024 /PRNewswire/ -- Black Health Matters (BHM) – a leading nonprofit health advocacy organization that provides health and wellness information to the Black community – will host its annual Black Health Matters Spring Health Summit and Expo in Washington, D.C. on Saturday, April 13.
  • After over a decade of hosting the popular health-focused summits, this will be the first in Washington, D.C. for Black Health Matters.
  • The Black Health Matters Spring Summit & Expo is sponsored by leading health organizations including Sanofi|Regeneron, Johnson & Johnson Health Care Systems, Johnson & Johnson Innovative Medicine, Research Includes Me, BMS, Sanofi, argenx, Vertex and CISCRP.
  • Notable partners are Howard University Hospital; DC Department of Health Care Finance; Precision Wellness; and American Association of Kidney Patients.